WallStSmart

Agilent Technologies Inc (A)vsMedpace Holdings Inc (MEDP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 179% more annual revenue ($7.07B vs $2.53B). A leads profitability with a 18.3% profit margin vs 17.8%. A appears more attractively valued with a PEG of 1.19. MEDP earns a higher WallStSmart Score of 70/100 (B-).

A

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 7.3Quality: 5.3
Piotroski: 3/9Altman Z: 1.99

MEDP

Strong Buy

70

out of 100

Grade: B-

Growth: 9.3Profit: 9.0Value: 10.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-318.5%)

Margin of Safety

-318.5%

Fair Value

$30.80

Current Price

$112.98

$82.18 premium

UndervaluedFair: $30.80Overvalued
MEDPUndervalued (+40.8%)

Margin of Safety

+40.8%

Fair Value

$716.04

Current Price

$466.80

$249.24 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 8.5/10
Return on EquityProfitability
20.0%9/10

Every $100 of equity generates 20 in profit

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

MEDP4 strengths · Avg: 9.0/10
Return on EquityProfitability
70.2%10/10

Every $100 of equity generates 70 in profit

Revenue GrowthGrowth
32.0%10/10

Revenue surging 32.0% year-over-year

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

EPS GrowthGrowth
26.9%8/10

Earnings expanding 26.9% YoY

Areas to Watch

A3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-3.6%2/10

Earnings declined 3.6%

MEDP3 concerns · Avg: 3.3/10
PEG RatioValuation
2.254/10

Expensive relative to growth rate

P/E RatioValuation
30.1x4/10

Premium valuation, high expectations priced in

Price/BookValuation
28.9x2/10

Trading at 28.9x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 22.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bull Case : MEDP

The strongest argument for MEDP centers on Return on Equity, Revenue Growth, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 21.6%. Revenue growth of 32.0% demonstrates continued momentum.

Bear Case : A

The primary concerns for A are Altman Z-Score, Piotroski F-Score, EPS Growth.

Bear Case : MEDP

The primary concerns for MEDP are PEG Ratio, P/E Ratio, Price/Book.

Key Dynamics to Monitor

A profiles as a mature stock while MEDP is a growth play — different risk/reward profiles.

MEDP carries more volatility with a beta of 1.46 — expect wider price swings.

MEDP is growing revenue faster at 32.0% — sustainability is the question.

MEDP generates stronger free cash flow (188M), providing more financial flexibility.

Bottom Line

MEDP scores higher overall (70/100 vs 61/100), backed by strong 17.8% margins and 32.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Medpace Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.

Want to dig deeper into these stocks?